Immunocore Holdings plc (NASDAQ:IMCR) Q4 2022 Earnings Call Transcript

Ralph Torbay: Great question. So we are seeing the treatment discontinuations to be in line with what we expected in the clinical trial experience. In fact, we look at closely the reasons for discontinuation and they’re really tracking very well. We’re not seeing any surprises, which is always great to see when you go into the real world. With regard to treatment beyond progression, what we do is we ask physicians, whether they are comfortable treating beyond progression. And then obviously, that’s part of our conversations that we have from a medical affairs perspective with physicians. And so far, we are seeing that level of comfort. Of course, as we go into the community, more education needs to be had, and that’s what we’re focused on.

Bahija Jallal: Yes. I think it’s a really good point because in the academic centers, there — the investigators are the ones who actually saw that there is benefit beyond progression. So I think there is more work to be done when we go into the community, but that’s where the MSLs and the education and the science will come in.

Operator: There are no further questions at this time. I would now like to hand the call back over to Bahija Jallal for any closing remarks.

Bahija Jallal: Yes. So, thank you so much for your questions, and thank you for your support, and we’re going to now close the call. Thank you.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.